Hepatitis C pharmacogenetics: State of the art in 2010

Nezam H. Afdhal, John G. McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean Michel Pawlotsky, Jeffrey S. Murray, Kevin V. Shianna, Yasuhito Tanaka, David L. Thomas, David R. Booth, David B. Goldstein

Research output: Contribution to journalArticle

Abstract

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

Original languageEnglish
Pages (from-to)336-345
Number of pages10
JournalHepatology
Volume53
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Pharmacogenetics
Hepatitis C
Hepacivirus
Interleukins
Genotype
Ribavirin
Interferon-alpha
Therapeutics
Economics
Genes

ASJC Scopus subject areas

  • Hepatology

Cite this

Afdhal, N. H., McHutchison, J. G., Zeuzem, S., Mangia, A., Pawlotsky, J. M., Murray, J. S., ... Goldstein, D. B. (2011). Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology, 53(1), 336-345. https://doi.org/10.1002/hep.24052

Hepatitis C pharmacogenetics : State of the art in 2010. / Afdhal, Nezam H.; McHutchison, John G.; Zeuzem, Stefan; Mangia, Alessandra; Pawlotsky, Jean Michel; Murray, Jeffrey S.; Shianna, Kevin V.; Tanaka, Yasuhito; Thomas, David L.; Booth, David R.; Goldstein, David B.

In: Hepatology, Vol. 53, No. 1, 01.2011, p. 336-345.

Research output: Contribution to journalArticle

Afdhal, NH, McHutchison, JG, Zeuzem, S, Mangia, A, Pawlotsky, JM, Murray, JS, Shianna, KV, Tanaka, Y, Thomas, DL, Booth, DR & Goldstein, DB 2011, 'Hepatitis C pharmacogenetics: State of the art in 2010', Hepatology, vol. 53, no. 1, pp. 336-345. https://doi.org/10.1002/hep.24052
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology. 2011 Jan;53(1):336-345. https://doi.org/10.1002/hep.24052
Afdhal, Nezam H. ; McHutchison, John G. ; Zeuzem, Stefan ; Mangia, Alessandra ; Pawlotsky, Jean Michel ; Murray, Jeffrey S. ; Shianna, Kevin V. ; Tanaka, Yasuhito ; Thomas, David L. ; Booth, David R. ; Goldstein, David B. / Hepatitis C pharmacogenetics : State of the art in 2010. In: Hepatology. 2011 ; Vol. 53, No. 1. pp. 336-345.
@article{048b66a610bc41d18db40894149cf3a5,
title = "Hepatitis C pharmacogenetics: State of the art in 2010",
abstract = "In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.",
author = "Afdhal, {Nezam H.} and McHutchison, {John G.} and Stefan Zeuzem and Alessandra Mangia and Pawlotsky, {Jean Michel} and Murray, {Jeffrey S.} and Shianna, {Kevin V.} and Yasuhito Tanaka and Thomas, {David L.} and Booth, {David R.} and Goldstein, {David B.}",
year = "2011",
month = "1",
doi = "10.1002/hep.24052",
language = "English",
volume = "53",
pages = "336--345",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Hepatitis C pharmacogenetics

T2 - State of the art in 2010

AU - Afdhal, Nezam H.

AU - McHutchison, John G.

AU - Zeuzem, Stefan

AU - Mangia, Alessandra

AU - Pawlotsky, Jean Michel

AU - Murray, Jeffrey S.

AU - Shianna, Kevin V.

AU - Tanaka, Yasuhito

AU - Thomas, David L.

AU - Booth, David R.

AU - Goldstein, David B.

PY - 2011/1

Y1 - 2011/1

N2 - In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

AB - In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=78751508078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751508078&partnerID=8YFLogxK

U2 - 10.1002/hep.24052

DO - 10.1002/hep.24052

M3 - Article

C2 - 21254181

AN - SCOPUS:78751508078

VL - 53

SP - 336

EP - 345

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 1

ER -